Advertisement

Contribution of monoaminergic mechanisms to the discriminative stimulus effects of 3,4-methylenedioxypyrovalerone (MDPV) in Sprague-Dawley rats

  • Harmony I. Risca
  • Lisa E. Baker
Original Investigation
  • 62 Downloads

Abstract

Rationale

3,4-Methylenedioxypyrovalerone (MDPV) is a popular synthetic cathinone reported to have a high abuse potential. Recent preclinical research indicates the psychopharmacology of MDPV is comparable to cocaine. Despite a recent influx of research on the psychopharmacology of MDPV, few studies have employed preclinical drug discrimination methods to discern the neurochemical mechanisms involved in its interoceptive stimulus effects.

Objective

The aim of this study was to evaluate a variety of monoaminergic agents for substitution, potentiation, or antagonism in rats trained to discriminate MDPV.

Methods

Male Sprague-Dawley rats were trained to discriminate 0.5 (experiment 1) or 1 mg/kg MDPV (experiment 2) from saline under an FR 20 schedule of food reinforcement. In experiment 1, MDMA, MDA, and their respective optical isomers (0.75–3 mg/kg), cocaine (2.5–20 mg/kg), GBR 12909 (5–40 mg/kg), and desipramine (3.2–10 mg/kg) were assessed for substitution. GBR 12909 (40 mg/kg) and desipramine (3.2 mg/kg) were subsequently assessed for potentiation of the MDPV cue. In experiment 2, stimulus antagonism tests were conducted with dopamine antagonists (Sch 23390, haloperidol) and serotonin antagonists (pirenperone, MDL100907, WAY 100635).

Results

The MDMA and MDA enantiomers produced divergent results, with virtually no substitution by (−)-MDMA or (−)-MDA, partial substitution with (+)-MDA, and full substitution with (+)-MDMA, as well as full substitution by the racemates, (±)-MDMA and (±)-MDA. Consistent with previous findings, cocaine fully substituted for MDPV. Although no dose of GBR 12909 or desipramine substituted for MDPV, these reuptake inhibitors enhanced the discriminative stimulus effects of lower MDPV doses. Both D1 (Sch 23390) and D2 (haloperidol) DA antagonists attenuated 1 mg/kg MDPV discrimination, whereas none of the 5-HT antagonists assessed altered MDPV discrimination.

Conclusions

These findings indicate MDPV’s interoceptive stimulus effects are mediated predominantly by dopaminergic actions, although serotonergic and/or noradrenergic modulation of these effects cannot be ruled out. Further investigations into the neurochemical actions involved in the discriminative stimulus effects of MDPV may serve to inform medication discovery and development for the treatment of MDPV abuse.

Keywords

3,4-Methylenedioxypyrovalerone Sprague-Dawley rats Synthetic cathinones Drug discrimination Dopamine 

Notes

Funding information

This research was supported by a grant from the National Institutes of Health (R15 DA038295). The National Institute on Drug Abuse Drug Control Supply Program and the National Institutes of Mental Health Chemical Synthesis and Drug Supply Program provided several of the drugs used in this study. A portion of this work (GBR 12909) was supported by the intramural research programs of the National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism.

Compliance with ethical standards

All procedures were reviewed and approved by the Western Michigan University Institutional Animal Care and Use Committee, and were in accordance with the guidelines of the Guide for the Care and Use of Laboratory Animals (National Research Council of the National Academies 2011).

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. Aarde SM, Huang PK, Creehan KM, Dickerson TJ, Taffe MA (2013) The novel recreational drug 3,4-methylenedioxypyrovalerone (MDPV) is a potent psychomotor stimulant: self-administration and locomotor activity in rats. Neuropharmacology 71:130–140.  https://doi.org/10.1016/j.neuropharm.2013.04.003 CrossRefPubMedPubMedCentralGoogle Scholar
  2. Aarde SM, Huang PK, Dickerson TJ, Taffe MA (2015) Binge-like acquisition of 3,4-methylenedioxypyrovalerone (MDPV) self-administration and wheel activity in rats. Psychopharmacology 232(11):1867–1877.  https://doi.org/10.1007/s00213-014-3819-4 CrossRefPubMedGoogle Scholar
  3. Andersen PH (1989) The dopamine uptake inhibitor GBR 12909: selectivity and molecular mechanism of action. Eur J Pharmacol 166:493–504.  https://doi.org/10.1016/0014-2999(89)90363-4 CrossRefPubMedGoogle Scholar
  4. Baker LE (2017) Hallucinogens in drug discrimination. In: Halberstadt AL, Vollenweider FX, Nichols DE (eds) Behavioral neurobiology of psychedelic drugs. Current Topics in Behavioral Neurosciences, vol 36. Springer, Berlin, Heidelberg, pp 201–219CrossRefGoogle Scholar
  5. Baker LE, Broadbent J, Michael EK, Matthews PK, Metosh CA, Saunders RB, West WB, Appel JB (1995) Assessment of the discriminative stimulus effects of the optical isomers of ecstasy (3,4-methylenedioxymethamphetamine; MDMA). Behav Pharmacol.  https://doi.org/10.1097/00008877-199504000-00007
  6. Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M, Rothman RB, Goldberg SR, Lupica CR, Sitte HH, Brandt SD, Tella SR, Cozzi NV, Schindler CW (2012) Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive ‘bath salts’ products. Neuropsychopharmacology 38:552.  https://doi.org/10.1038/npp.2012.204 CrossRefPubMedPubMedCentralGoogle Scholar
  7. Berquist MD, Baker LE (2017) Characterization of the discriminative stimulus effects of 3,4-methylenedioxypyrovalerone in male Sprague-Dawley rats. Behav Pharmacol 28:394–400.  https://doi.org/10.1097/FBP.0000000000000310 CrossRefPubMedPubMedCentralGoogle Scholar
  8. Broadbent J, Appel JB, Michael EK, Ricker JH (1992) Discriminative stimulus effects of the optical isomers of 3,4-methylenedioxyamphetamine (MDA). Behav Pharmacol 3:443–454.  https://doi.org/10.1097/00008877-199210000-00003 CrossRefPubMedGoogle Scholar
  9. Callahan PM, Appel JB (1988) Differences in the stimulus properties of 3, 4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine in animals trained to discriminate hallucinogens from saline. J Pharmacol Exp Ther 246:866–870 http://jpet.aspetjournals.org/content/246/3/866 PubMedGoogle Scholar
  10. Cameron KN, Kolanos R, Solis E, Glennon RA, De Felice LJ (2013) Bath salts components mephedrone and methylenedioxypyrovalerone (MDPV) act synergistically at the human dopamine transporter. Br J Pharmacol 168:1750–1757.  https://doi.org/10.1111/bph.12061 CrossRefPubMedPubMedCentralGoogle Scholar
  11. Centers for Disease Control and Prevention (CDC) (2011) Emergency department visits after use of a drug sold as “bath salts”—Michigan, November 13, 2010—March 31, 2011. Morbidity and mortality weekly report 60, MMWR, pp. 624–627. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6019a6.htm. Accessed 26 Feb 2018
  12. Cunningham KA, Callahan PM (1991) Monoamine reuptake inhibitors enhance the discriminative state induced by cocaine in the rat. Psychopharmacology 104:177–180.  https://doi.org/10.1007/BF02244175 CrossRefPubMedGoogle Scholar
  13. Eshleman AJ, Wolfrum KM, Hatfield MG, Johnson RA, Murphy KV, Janowsky A (2013) Substituted methcathinones differ in transporter and receptor interactions. Biochem Pharmacol 85:1803–1815.  https://doi.org/10.1016/j.bcp.2013.04.004 CrossRefPubMedPubMedCentralGoogle Scholar
  14. Fantegrossi WE, Gannon BM, Zimmerman SM, Rice KC (2013) In vivo effects of abused ‘bath salt’ constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice: drug discrimination, thermoregulation, and locomotor activity. Neuropsychopharmacology 38:563.  https://doi.org/10.1038/npp.2012.233 CrossRefPubMedGoogle Scholar
  15. Froberg, Froberg BA, Levine M, Beuhler MC, Judge BS, Moore PW, Engebretsen KM, Mckeown NJ, Rosenbaum CD, Young AC, Rusyniak DE, ACMT Toxicology Investigators Consortium (2015) Acute methylenedioxypyrovalerone toxicity. J Med Toxicol 11:185–194.  https://doi.org/10.1007/s13181-014-0446-8 CrossRefPubMedGoogle Scholar
  16. Gannon BM, Williamson A, Suzuki M, Rice KC, Fantegrossi WE (2016) Stereoselective effects of abused “bath salt” constituent 3,4-methylenedioxypyrovalerone in mice: drug discrimination, locomotor activity, and thermoregulation. J Pharmacol Exp Ther 356:615–623.  https://doi.org/10.1124/jpet.115.229500 CrossRefPubMedPubMedCentralGoogle Scholar
  17. Gannon BM, Galindo KI, Rice KC, Collins GT (2017) Individual differences in the relative reinforcing effects of 3,4-methylenedioxypyrovalerone under fixed and progressive ratio schedules of reinforcement in rats. J Pharmacol Exp Ther 361:181–189.  https://doi.org/10.1124/jpet.116.239376 CrossRefPubMedPubMedCentralGoogle Scholar
  18. Gatch MB, Taylor CM, Forster MJ (2013) Locomotor stimulant and discriminative stimulus effects of ‘bath salt’ cathinones. Behav Pharmacol 24:437–447.  https://doi.org/10.1097/fbp.0b013e328364166d CrossRefPubMedPubMedCentralGoogle Scholar
  19. Glennon RA, Young R (1984) MDA: an agent that produces stimulus effects similar to those of 3,4-DMA, LSD and cocaine. Eur J Pharmacol 99:249–250.  https://doi.org/10.1016/0014-2999(84)90250-4 CrossRefPubMedGoogle Scholar
  20. Glennon RA, Young R (2011) Drug discrimination: applications to medicinal chemistry and drug studies. Wiley, HobokenCrossRefGoogle Scholar
  21. Goodwin AK, Baker LE (2000) A three-choice discrimination procedure dissociates the discriminative stimulus effects of d-amphetamine and (±)-MDMA in rats. Exp Clin Psychopharmacol 8:415–423.  https://doi.org/10.1037//1064-1297.8.3.415 CrossRefPubMedGoogle Scholar
  22. Goodwin AK, Pynnonen DM, Baker LE (2003) Serotonergic–dopaminergic mediation of MDMAs discriminative stimulus effects in a three-choice discrimination. Pharmacol Biochem Behav 74:987–995.  https://doi.org/10.1016/s0091-3057(03)00029-7 CrossRefPubMedGoogle Scholar
  23. Harvey EL, Baker LE (2016) Differential effects of 3,4-methylenedioxypyrovalerone (MDPV) and 4-methylmethcathinone (mephedrone) in rats trained to discriminate MDMA or a d-amphetamine MDMA mixture. Psychopharmacology 233:673–680.  https://doi.org/10.1007/s00213-015-4142-4 CrossRefPubMedGoogle Scholar
  24. Harvey EL, Burroughs RL, Baker LE (2017) Effects of D1 and D2 receptor antagonists on the discriminative stimulus effects of methylendioxypyrovalerone and mephedrone in male Sprague-Dawley rats trained to discriminate D-amphetamine. Behav Pharmacol 28:586–589.  https://doi.org/10.1097/fbp.0000000000000328 CrossRefPubMedPubMedCentralGoogle Scholar
  25. King HE, Wakeford A, Taylor W et al (2015a) Sex differences in 3,4-methylenedioxypyrovalerone (MDPV)-induced taste avoidance and place preferences. Pharmacol Biochem Behav 137:16–22.  https://doi.org/10.1016/j.pbb.2015.07.013 CrossRefPubMedPubMedCentralGoogle Scholar
  26. King HE, Wetzell B, Rice K, Riley A (2015b) An assessment of MDPV-induced place preference in adult Sprague-Dawley rats. Drug Alcohol Depend.  https://doi.org/10.1016/j.drugalcdep.2015.07.310
  27. Matecka D, Rothman RB, Radesca L, de Costa BR, Dersch CM, Partilla JS, Pert A, Glowa JR, Wojnicki FH, Rice KC (1996) Development of novel, potent, and selective dopamine reuptake inhibitors through alteration of the piperazine ring of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909). J Med Chem 39:4704–4716.  https://doi.org/10.1021/jm960305h CrossRefPubMedGoogle Scholar
  28. National Drug Intelligence Center (2011) Situation report: synthetic cathinones (bath salts): an emerging domestic threat. National Drug Intelligence Center, Johnstown, pp 15901–11622 http://www.justice.gov/archive/ndic/pubs44/44571/44571p.pdf. Accessed 28 May 2018Google Scholar
  29. National Research Council of the National Academies (2011) Guide for the Care and use of laboratory animals, 8th ed. Washington D.C., The National Academies PressGoogle Scholar
  30. Ross EA, Reisfield GM, Watson MC et al (2012) Psychoactive “bath salts” intoxication with methylenedioxypyrovalerone. Am J Med 125:854–858.  https://doi.org/10.1016/j.amjmed.2012.02.019 CrossRefPubMedGoogle Scholar
  31. Schindler CW, Thorndike EB, Goldberg SR, Lehner KR, Cozzi NV, Brandt SD, Baumann MH (2016) Reinforcing and neurochemical effects of the “bath salts” constituents 3,4-methylenedioxypyrovalerone (MDPV) and 3,4-methylenedioxy-N-methylcathinone (methylone) in male rats. Psychopharmacology 233:1981–1990.  https://doi.org/10.1007/s00213-015-4057-0 CrossRefPubMedGoogle Scholar
  32. Simmler L, Buser T, Donzelli M, Schramm Y, Dieu LH, Huwyler J, Chaboz S, Hoener MC, Liechti ME (2013) Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 168:458–470.  https://doi.org/10.1111/j.1476-5381.2012.02145.x CrossRefPubMedGoogle Scholar
  33. Spiller HA, Ryan ML, Weston RG, Jansen J (2011) Clinical experience with and analytical confirmation of “bath salts” and “legal highs” (synthetic cathinones) in the United States. Clin Toxicol 49:499–505.  https://doi.org/10.3109/15563650.2011.590812 CrossRefGoogle Scholar
  34. Stolerman IP, Childs E, Ford MM, Grant KA (2011) Role of training dose in drug discrimination: a review. Behav Pharmacol 22:415–429.  https://doi.org/10.1097/FBP.0b013e328349ab37 CrossRefPubMedPubMedCentralGoogle Scholar
  35. Tella SR, Goldberg SR (2001) Subtle differences in the discriminative stimulus effects of cocaine and GBR-12909. Prog Neuro-Psychopharmacol Biol Psychiatry 25:639–656.  https://doi.org/10.1016/S0278-5846(00)00180-9 CrossRefGoogle Scholar
  36. UNODC (2015) United Nations Office on Drugs and Crime: World Drug Report 2015. United Nations publication, New York http://www.undoc.org/documents/wdr2015/World_Drug_Report_2015.pdf. Accessed 29 June 2018CrossRefGoogle Scholar
  37. Valente MJ, De Pinho PG, de Lourdes Bastos M, Carvalho F, Carvalho M (2014) Khat and synthetic cathinones: a review. Arch Toxicol 88:15–45.  https://doi.org/10.1007/s00204-013-1163-9 CrossRefPubMedGoogle Scholar
  38. Watterson LR, Kufahl PR, Nemirovsky NE, Sewalia K, Grabenauer M, Thomas BF, Marusich JA, Wegner S, Olive MF (2014) Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV). Addict Biol 19:165–174.  https://doi.org/10.1111/j.1369-1600.2012.00474.x CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of PsychologyWestern Michigan UniversityKalamazooUSA

Personalised recommendations